Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Exiqon has signed a collaborative research agreement with the Kleberg Center for Molecular Markers at the University of Texas MD Anderson Cancer Center to discover microRNA based biomarkers for breast cancer.
Subscribe to our email newsletter
Under this agreement, Exiqon will use its miRCURY, LNA products to discover microRNA biomarkers. Specifically, the project focuses on identifying miRNA expression signatures associated with relapse and progression of breast cancer, and to develop and validate diagnostic tools that will guide patient management.
Lars Kongsbak, president and CEO of Exiqon, said: “This collaboration is another important step for Exiqon on our path to develop microRNA based cancer diagnostics. This agreement with the MD Anderson will enable us to develop diagnostic products based on our LNA technology to support major advances in cancer research and cancer diagnostics.”